Plasticell Spins Out Regenerative Drug Discovery Venture

New demerged business called ‘Progenitor Labs’

15-Apr-2011 - United Kingdom

Plasticell Ltd has announced today that following its recent £3.5m financing, it has undergone a strategic re-structuring to enable the Company to focus on its award winning CombiCult™ technology for stem cell differentiation. Consequently, Plasticell Ltd has demerged its regenerative drug discovery unit into a newly established company, Progenitor Labs Limited.

Progenitor Labs has been assigned all rights to Plasticell’s proprietary ProScreen™ (formerly CombiScreen™) technology for the discovery of small molecule drugs capable of regenerating tissues of the human body, and has acquired an exclusive license to CombiCult™ technology solely for the purpose of creating high quality, physiologically relevant progenitor cells for use in ProScreen™.

Dr Yen Choo, the founder behind Plasticell and Progenitor Labs, commented: “Regenerative drugs are an attractive alternative to the use of cells in regenerative medicine. Drugs are relatively easier to develop, manufacture, package, distribute and administer, and have clearer regulatory and reimbursement processes. Crucially, this business model is aligned with that of the pharmaceutical companies that specialise in discovering and marketing small molecule therapeutics.”

As part of the re-organisation, Dr Choo will transfer to Progenitor Labs to lead development of the spin-out, while Mr Dennis Saw and Dr Lilian Hook will be promoted to the posts of CEO and Research Director of Plasticell, respectively. Dr Choo will continue to direct the company’s scientific and business strategy as the Executive Chairman.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance